Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China

BackgroundClinical guidelines generally recommend endocrine therapy (ET) as first-line treatment of hormone receptor-positive advanced breast cancer (HR+ ABC) whereas chemotherapy (CT) should be considered in the presence of life-threatening disease or limited clinical benefit after three sequential...

Full description

Bibliographic Details
Main Authors: Yun Wu, Yiqun Han, Pei Yu, Quchang Ouyang, Min Yan, Xiaojia Wang, Xichun Hu, Zefei Jiang, Tao Huang, Zhongsheng Tong, Shusen Wang, Yongmei Yin, Hui Li, Runxiang Yang, Huawei Yang, Yuee Teng, Tao Sun, Li Cai, Hongyuan Li, Xi Chen, Jianjun He, Xinlan Liu, Shune Yang, Youlin Qiao, Jinhu Fan, Jiayu Wang, Binghe Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
advanced breast cancer
endocrine treatment
epidemiological study
hormone receptor-positive
nationwide survey
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.599604/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.599604/full

Similar Items